Epsilon Healthcare Ltd (ASX: EPN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Epsilon Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$7.21 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
300.35 million
Earnings per share
-0.011
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Epsilon Healthcare Ltd (ASX: EPN)
Latest News
Share Fallers
Can ASX cannabis shares rebound in 2020?
Share Gainers
Why Adairs, Gold Road, oOh!Media, & THC Global shares are storming higher
Share Gainers
THC Global share price surges 11% higher on cannabis production update
Share Fallers
Elixinol share price slumps 6% after sale of Japanese cannabis arm
Share Gainers
Why this ASX cannabis stock is surging higher today
Share Gainers
Why this ASX cannabis stock rocketed 13% higher yesterday
Share Gainers
Why THC Global and these ASX cannabis shares are rocketing higher today
Share Fallers
Why these ASX cannabis shares were crushed in October
52-Week Lows
Why these ASX cannabis shares are being smoked
Speculative
Weekly ASX cannabis share news
Share Market News
Should you still be invested in ASX marijuana shares?
Share Gainers
Why has the THC share price climbed 13% in 2 days?
EPN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Epsilon Healthcare Ltd
Epsilon Healthcare Ltd is a diversified global healthcare and pharmaceuticals company. It owns number of medicinal cannabis assets including the cannabis manufacturing facility in the Southern Hemisphere, the Tetra Health clinic, and the Medimar Platform an end to end ecommerce solution for nutraceuticals and cannabis. EPN additionally operates a turn-key cannabis cultivation solutions provider based in Vancouver, Canada.
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Alan Preston Beasley | Non-Executive DirectorNon-Executive Deputy Chairman | Aug 2016 |
Mr Beasley has worked in the Investment Banking and Investment Management Industries for over 30 years with BankersTrust Australia, Goldman Sacks Asset Management, BNP Paribas Asset Management Ltd. The last two positions as Managing Director and Australian Country Head. Mr Beasley is a Director and former Director of several listed and unlisted public and private companies including two public charities.
|
| Mr Peter Giannopoulos | Chief Executive OfficerExecutive Director | May 2023 |
Mr Giannopoulos brings to Epsilon, more than 25 years experience across the Australian healthcare ecosystems including success within the ASX healthcare setting and success in leadership, operations, M&A, GMP manufacturing & the delivery of innovative revenue, and market accretive opportunities Most recently Peter was CEO of Cell Therapies Pty Ltd, an Australian based globally active commercial contract development and manufacturing company with a specialisation in cell and gene therapies and cellular immunotherapy products. At Cell Therapies, Peter introduced corporate strategies and controls and a trajectory for growth, including undertaking capital raising activities to support the organisation to achieve revenue growth in coming years as it capitalises on local and global manufacturing opportunities in the cell and gene therapy landscape. Prior to Cell Therapies Pty Ltd, Peter led the diversification of Australia largest private hospital provider, Ramsay Healthcare (ASX: RHC) as the CEO of the Ramsay Pharmacy Group over a 12 year period. As the executive who developed and led the expansion of the Ramsay Pharmacy Group from a single site in 2007. Peter also has a clinical background with a degree in pharmacy and a deep understanding of the Australian and international health landscapes.
|
| Ms Zoe Hutchings | Non-Executive Director | Jun 2024 |
--
|
| Mr Richard Phillip Legge | Company Secretary | Aug 2024 |
-
|
| Mr Marcelo Mora | Company Secretary | Dec 2022 |
-
|
| Richard Phillip Legge | Company Secretary |
-
|
|
| Marcelo Mora | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Watercrest Asset Management Pty Ltd | 35,828,878 | 11.93% |
| Fennell Church Pty Ltd | 8,438,499 | 2.81% |
| Mr Craig Graeme Chapman <Nampac Discretionary A/C> | 7,500,000 | 2.50% |
| Health360 Investment Management Inc | 7,052,880 | 2.35% |
| Cannim Group Pty Ltd | 5,555,556 | 1.85% |
| Filmrim Pty Ltd | 4,465,755 | 1.49% |
| Barcoo Holdings Pty Ltd <Wyan Family Investments> | 3,795,824 | 1.26% |
| Karantzias Investments Pty Ltd <Karantzias Family A/C> | 3,636,364 | 1.21% |
| Sckld Investments Pty Ltd <Sckld Holdings A/C> | 3,593,894 | 1.20% |
| Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> | 3,055,650 | 1.02% |
| Mr George Daaboul | 3,000,000 | 1.00% |
| Meta Growth Corp | 2,942,489 | 0.98% |
| Celtic Capital Pty Ltd | 2,888,872 | 0.96% |
| Tiger Pty Ltd <Tiger Commercial Unit Trust> | 2,545,455 | 0.85% |
| Barcoo Holdings Pty Ltd <Maple Ventures> | 2,438,341 | 0.81% |
| Htgr Investments Pty Ltd | 2,298,765 | 0.77% |
| Mrs Chongna Wang | 2,046,035 | 0.68% |
| Mr Alan Roseby Barkas + Mrs Lee Margaret Barkas <Barkas Super | 2,000,000 | 0.67% |
| Mr Craig Graeme Chapman <Nampac Discretionary A/C> (i) | 1,958,684 | 0.65% |
| Citicorp Nominees Pty Limited | 1,598,988 | 0.53% |
